FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3108771721> ?p ?o ?g. }

• W3108771721 endingPage "175" @default.
• W3108771721 startingPage "175" @default.
• W3108771721 abstract "Pinkel D. Treatment of childhood acute lymphocytic leukemia. J Pediatr 1970;77:1089-91. Acute lymphoblastic leukemia (ALL) is the most common malignancy in childhood and the most curable disease in pediatric oncology. In the 1960s, ALL was an almost uniformly fatal disease, but due to new therapies and breakthroughs in the last 50 years, the current 5-year survival rate has improved to 89% in children and 61% in young adults.1Brown P. Inaba H. Annesley C. Beck J. Colace S. Dallas M. et al.Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw. 2020; 18: 81-112Crossref PubMed Scopus (19) Google Scholar The essence of ALL treatment remains the same and continues to be grouped in the following phases: induction, consolidation, and a prolonged maintenance. One of the most significant changes is the individualization of each patient, classifying them according to risk stratification, predictive biomarkers, molecular prognosis, and monitoring of minimal residual disease, aiming to reduce complications and mortality of chemotherapy itself. Another major shift includes central nervous system prophylaxis, an essential part of ALL management and a prerequisite for successful treatment.2Rafei H. Kantarjian H.M. Jabbour E.J. Recent advances in the treatment of acute lymphoblastic leukemia.Leuk Lymphoma. 2019; 60: 2606-2621Crossref Scopus (15) Google Scholar Fifty years ago, “complete remission” was based on Bisel morphologic criteria, which Pinkel considered insufficient, as it excluded central nervous system involvement. Today, analytic minimal residual disease testing using flow cytometry is a strong prognostic indicator in all leukemia subtypes.3Kaplan J.A. Leukemia in children.Pediatr Rev. 2019; 40: 319-331Crossref Scopus (11) Google Scholar The last decade has seen significant advances in treatment; thanks to molecular biology, Paul Ehrlich's “magic bullet” concept is reaching its full realization. Today, we are in the era of monoclonal antibody therapy with new drugs such as blinatumomab, inotuzumab, and chimeric antigen receptor T cells, which target specific abnormal molecules and pathways of cancer cells.2Rafei H. Kantarjian H.M. Jabbour E.J. Recent advances in the treatment of acute lymphoblastic leukemia.Leuk Lymphoma. 2019; 60: 2606-2621Crossref Scopus (15) Google Scholar These new therapies came with new complications and adverse effects, so the imperative to improve supportive care, comfort, and quality of life remains. However, they pave the way to a future in which treatment toxicity for patients is minimized. The challenges of 50 years ago are being today addressed with the goal to completely phase out conventional chemotherapy." @default.
• W3108771721 created "2020-12-07" @default.
• W3108771721 creator A5013554989 @default.
• W3108771721 creator A5019815538 @default.
• W3108771721 creator A5084232801 @default.
• W3108771721 date "2020-12-01" @default.
• W3108771721 modified "2023-09-30" @default.
• W3108771721 title "50 Years Ago in T J P" @default.
• W3108771721 doi "https://doi.org/10.1016/j.jpeds.2020.07.072" @default.
• W3108771721 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33228911" @default.
• W3108771721 hasPublicationYear "2020" @default.
• W3108771721 type Work @default.
• W3108771721 sameAs 3108771721 @default.
• W3108771721 citedByCount "0" @default.
• W3108771721 crossrefType "journal-article" @default.
• W3108771721 hasAuthorship W3108771721A5013554989 @default.
• W3108771721 hasAuthorship W3108771721A5019815538 @default.
• W3108771721 hasAuthorship W3108771721A5084232801 @default.
• W3108771721 hasBestOaLocation W31087717211 @default.
• W3108771721 hasConcept C126322002 @default.
• W3108771721 hasConcept C143998085 @default.
• W3108771721 hasConcept C187212893 @default.
• W3108771721 hasConcept C2776694085 @default.
• W3108771721 hasConcept C2778461978 @default.
• W3108771721 hasConcept C2779134260 @default.
• W3108771721 hasConcept C2779338263 @default.
• W3108771721 hasConcept C2779399171 @default.
• W3108771721 hasConcept C2779823535 @default.
• W3108771721 hasConcept C2909962599 @default.
• W3108771721 hasConcept C71924100 @default.
• W3108771721 hasConceptScore W3108771721C126322002 @default.
• W3108771721 hasConceptScore W3108771721C143998085 @default.
• W3108771721 hasConceptScore W3108771721C187212893 @default.
• W3108771721 hasConceptScore W3108771721C2776694085 @default.
• W3108771721 hasConceptScore W3108771721C2778461978 @default.
• W3108771721 hasConceptScore W3108771721C2779134260 @default.
• W3108771721 hasConceptScore W3108771721C2779338263 @default.
• W3108771721 hasConceptScore W3108771721C2779399171 @default.
• W3108771721 hasConceptScore W3108771721C2779823535 @default.
• W3108771721 hasConceptScore W3108771721C2909962599 @default.
• W3108771721 hasConceptScore W3108771721C71924100 @default.
• W3108771721 hasLocation W31087717211 @default.
• W3108771721 hasOpenAccess W3108771721 @default.
• W3108771721 hasPrimaryLocation W31087717211 @default.
• W3108771721 hasRelatedWork W2052505636 @default.
• W3108771721 hasRelatedWork W2100358456 @default.
• W3108771721 hasRelatedWork W2183264040 @default.
• W3108771721 hasRelatedWork W2252760054 @default.
• W3108771721 hasRelatedWork W2413263178 @default.
• W3108771721 hasRelatedWork W2418294496 @default.
• W3108771721 hasRelatedWork W2428449797 @default.
• W3108771721 hasRelatedWork W3032750421 @default.
• W3108771721 hasRelatedWork W3126671384 @default.
• W3108771721 hasRelatedWork W2184959765 @default.
• W3108771721 hasVolume "227" @default.
• W3108771721 isParatext "false" @default.
• W3108771721 isRetracted "false" @default.
• W3108771721 magId "3108771721" @default.
• W3108771721 workType "article" @default.